Immunity and immunopathology to respiratory syncytial virus. The mouse model
- PMID: 7551415
- DOI: 10.1164/ajrccm/152.4_Pt_2.S59
Immunity and immunopathology to respiratory syncytial virus. The mouse model
Abstract
Infection with respiratory syncytial virus (RSV) is a major unsolved challenge for vaccine development. RSV is worldwide in distribution and infects almost all children during the first 2 yr of life. The mouse model of RSV lung disease has been very successful in reproducing many aspects of the human disease. In particular, the role of antiviral T cells in both eliminating virus and causing enhanced disease has been shown dramatically. This immunopathologic paradox is now more clearly understood than for any other common human infection, largely due to insights gained from the mouse model. This review focuses on the unique ability of different RSV proteins to prime for specific functional subsets in the mouse, and the association between sensitization to the major surface glycoprotein G, the induction of T helper 2 cells, and the subsequent appearance of lung eosinophilia during RSV infection.
Similar articles
-
Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.Virology. 2000 Mar 30;269(1):54-65. doi: 10.1006/viro.2000.0186. Virology. 2000. PMID: 10725198
-
Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.J Immunol. 1998 Dec 1;161(11):6215-22. J Immunol. 1998. PMID: 9834108
-
Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.J Virol. 2015 May;89(9):5022-31. doi: 10.1128/JVI.03630-14. Epub 2015 Feb 18. J Virol. 2015. PMID: 25694607 Free PMC article.
-
The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus.Dev Biol Stand. 1998;92:179-85. Dev Biol Stand. 1998. PMID: 9554273 Review.
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
Cited by
-
Peripheral blood T cells response in human parainfluenza virus-associated lower respiratory tract infection in children.Saudi J Biol Sci. 2020 Oct;27(10):2847-2852. doi: 10.1016/j.sjbs.2020.07.005. Epub 2020 Jul 10. Saudi J Biol Sci. 2020. PMID: 32994745 Free PMC article.
-
Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.J Virol. 2000 Feb;74(4):1614-22. doi: 10.1128/jvi.74.4.1614-1622.2000. J Virol. 2000. PMID: 10644330 Free PMC article.
-
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8996-9001. doi: 10.1073/pnas.0409478102. Epub 2005 Jun 14. Proc Natl Acad Sci U S A. 2005. PMID: 15956195 Free PMC article.
-
The use of a neonatal mouse model to study respiratory syncytial virus infections.Expert Rev Anti Infect Ther. 2010 Dec;8(12):1371-80. doi: 10.1586/eri.10.125. Expert Rev Anti Infect Ther. 2010. PMID: 21133663 Free PMC article. Review.
-
Disrupting Bordetella Immunosuppression Reveals a Role for Eosinophils in Coordinating the Adaptive Immune Response in the Respiratory Tract.Microorganisms. 2020 Nov 17;8(11):1808. doi: 10.3390/microorganisms8111808. Microorganisms. 2020. PMID: 33212993 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical